Les Henderson
University of Wisconsin–Madison(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Cancer, Hypoxia, and Metabolism, Radiomics and Machine Learning in Medical Imaging
Most-Cited Works
- → Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer(2015)532 cited
- → Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition(2018)271 cited
- → Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence(2011)112 cited
- → RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma(2011)103 cited
- → Copy Number Variation of CCL3-like Genes Affects Rate of Progression to Simian-AIDS in Rhesus Macaques (Macaca mulatta)(2009)68 cited
- → Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue(2014)54 cited
- → Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease(2010)46 cited
- → Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH(2015)43 cited
- → Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.(2013)39 cited
- → A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.(2012)20 cited